[8-K] AYTU BioPharma, Inc. Reports Material Event

Rhea-AI Filing Summary

On June 20, 2025, Aytu BioPharma, Inc. (AYTU) executed Amendment No. 6 to its Loan and Security Agreement with Eclipse Business Capital. The amendment affects both the company’s term loan and revolving credit facility.

• Maturity extension: The $13.0 million Eclipse Term Loan and the Eclipse Revolving Loan now mature on June 12, 2029, giving AYTU an additional four-year runway.
• Incremental liquidity: A $1.5 million incremental advance was added to the revolving facility, priced at SOFR + 5.50%.
• Amortisation schedule: Repayment of the incremental advance begins August 1, 2025 at $125,000 per month until the advance is fully repaid.
• Borrowing-base flexibility: The amendment increases borrowing-base availability by permitting 25% concentration limits on certain independent pharmacy distributors.
• Regulatory disclosure: The transaction constitutes a direct financial obligation (Item 2.03). A press release dated June 23, 2025 (Exhibit 99.1) publicised the amendment; no earnings or operational updates were included.

The deal strengthens near-term liquidity and extends debt maturities, though at a relatively high floating rate and with scheduled principal reductions that will affect future cash flow.

Positive

• Maturity of both term and revolver extended to June 12, 2029, eliminating near-term refinancing pressure.
• $1.5 million incremental advance increases immediate borrowing capacity for working-capital needs.
• Relaxed 25% customer concentration limit can boost borrowing-base availability, improving liquidity flexibility.

Negative

• Interest rate set at SOFR + 5.50% is costly, raising future interest expense.
• Monthly principal payments of $125,000 start August 1, 2025, creating a fixed cash outflow.
• Total outstanding principal of $13 million increases leverage on the balance sheet.

Insights

Financial Analyst

TL;DR: Debt maturity pushed to 2029 and $1.5 m revolver boost improve liquidity; high SOFR+5.50% cost and monthly amortisation temper benefit.

Analysis: Extending both the term loan and revolver to 2029 removes a medium-term refinancing overhang and signals lender confidence in AYTU’s credit profile. The additional $1.5 million borrowing capacity, though modest, could support working-capital needs as the company advances its product portfolio. However, pricing at SOFR + 5.50% (currently >10% all-in) is expensive and will pressure interest expense. The $125,000 monthly pay-down beginning August 2025 introduces a fixed cash drain of roughly $1.5 million per year, which investors should weigh against expected operating cash burn. Net impact: modestly positive for liquidity, neutral to mildly dilutive for earnings.

Risk Analyst

TL;DR: Longer tenor lowers refinancing risk; higher leverage and floating-rate exposure heighten interest-rate and covenant compliance risk.

Analysis: Moving the maturity to 2029 reduces default probability tied to near-term debt walls. Nevertheless, outstanding principal now totals $13 million, increasing leverage. With SOFR at multi-year highs, every 100 bp rise adds roughly $130,000 to annual interest expense. The scheduled monthly amortisation may strain liquidity if product sales underperform. The relaxed customer concentration limits could expand eligible receivables but also raise counter-party exposure. Overall risk profile shifts from short-term rollover risk to longer-term interest-rate and covenant-compliance risk—classified as neutral in aggregate.

false 0001385818 0001385818 2025-06-20 2025-06-20

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

June 20, 2025

Date of Report (Date of earliest event reported)

AYTU BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38247		47-0883144
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7900 East Union Avenue, Suite 920

Denver, CO 80237

(Address of principal executive offices, including zip code)

(720) 437-6580

(Registrant’s telephone number, including area code)

Not applicable 

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share		AYTU		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On June 20, 2025, Aytu BioPharma, Inc. (“Aytu” or the “Company”) entered into an Amendment No. 6 to Loan and Security Agreement (the “Eclipse Amendment”), by and among the Company, Neos Therapeutics, Inc., Neos Therapeutics Brands, LLC, Neos Therapeutics, LP, Aytu Therapeutics, LLC, PharmaFab Texas, LLC and Cherry Creek Therapeutics, Inc. (collectively, the “Borrowers”), Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC), as agent, and the lenders party thereto (agent and such lenders, collectively, the “Eclipse Lender”).

Pursuant to the Eclipse Amendment, the Eclipse Lender (i) extended the term loan (the “Eclipse Term Loan”) maturity date to June 12, 2029, and increased the Eclipse Term Loan resulting in an outstanding principal amount of $13.0 million on the closing date of the Eclipse Amendment, (ii) extended the revolving credit facility (the “Eclipse Revolving Loan”) maturity date to June 12, 2029, and increased the potential maximum borrowing base pursuant to a $1.5 million incremental advance (the “Eclipse Incremental Advance”), at an interest rate of the SOFR plus 5.50%, with repayment and permanent reduction of such Eclipse Incremental Advance commencing August 1, 2025, and continuing on the first day of each calendar month thereafter, in an amount equal to $125,000 per month until the Eclipse Incremental Advance has been reduced to $0 and (iii) revised the borrowing base supporting the Eclipse Revolving Loan by permitting concentration limits on certain independent pharmacy distributors of 25%.

The foregoing description of the Eclipse Amendment is not complete and is qualified in its entirety by reference to the Eclipse Amendment, filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

The Company issued a press release on June 23, 2025, announcing the transactions described herein, which is attached as Exhibit 99.1 to this report.

The information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Exhibit Description
10.1*		Amendment No. 6 to Loan and Security Agreement dated June 20, 2025, between the Borrowers and lenders party thereto and Eclipse Business Capital LLC as agent
99.1		Press Release dated June 23, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

*    Pursuant to Item 601(b)(10) of Regulation S-K, portions of this exhibit (indicated by asterisks) have been omitted as the registrant has determined that (1) the omitted information is not material and (2) the omitted information would likely cause competitive harm to the registrant if publicly disclosed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AYTU BIOPHARMA, INC.
Date: June 23, 2025	By:	/s/ Ryan J. Selhorn
		Ryan J. Selhorn
		Chief Financial Officer

FAQ

What did AYTU BioPharma announce in its June 20, 2025 Form 8-K?

The company amended its loan agreement, extending debt maturities to 2029 and adding a $1.5 million incremental revolving advance.

How much debt does AYTU owe under the new Eclipse Term Loan?

The outstanding principal on the term loan is $13.0 million as of the amendment’s closing date.

When does repayment of the incremental advance begin?

Repayment starts on August 1, 2025 at $125,000 per month.

What is the interest rate on AYTU’s new revolving advance?

The incremental advance bears interest at SOFR plus 5.50%.

How long is the new maturity for AYTU’s term loan and revolver?

Both facilities now mature on June 12, 2029.

Did the filing include any earnings or product updates?

No. The 8-K focused solely on the loan amendment; it contained no earnings or operational disclosures.